Blog

Jim Omel: I’ve sat on both sides of the exam table and would avoid marginally effective treatments

Photo from Jim Omel/X

Jul 31, 2024, 06:54

Jim Omel: I’ve sat on both sides of the exam table and would avoid marginally effective treatments

Jim Omel, Patient Advocate, shared on X:

“Patients’ considerations of time toxicity when assessing cancer treatments with marginal benefit.

I’ve sat on both sides of the exam table as MD, and as cancer patient. I HATE spending time in offices and Prescription centers, and would avoid marginally effective treatments.”

Patients’ considerations of time toxicity when assessing cancer treatments with marginal benefit

Autors: Arjun Gupta, Michael D Brundage, Jacqueline Galica, Safiya Karim, Rachel Koven, Terry L Ng, Jennifer O’Donnell, Julia tenHove, Andrew Robinson, Christopher M Booth,

Jim Omel

Source: Jim Omel/X

Andrew Robinson Arjun Gupta cancer cancer treatments Christopher M. Booth Jacqueline Galica Jennifer O’Donnell Jim Omel Julia TenHove Michael D Brundage OncoDaily Oncology Rachel Koven Safiya Karim Terry L Ng

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage